In December 2019, the world started to face a new pandemic situation, the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). Although coronavirus disease (COVID-19) clinical manifestations are mainly respiratory, major cardiac complications are being reported. Cardiac manifestations etiology seems to be multifactorial, comprising direct viral myocardial damage, hypoxia, hypotension, enhanced inflammatory status, ACE2-receptors downregulation, drug toxicity, endogenous catecholamine adrenergic status, among others. Studies evaluating patients with COVID-19 presenting cardiac injury markers show that it is associated with poorer outcomes, and arrhythmic events are not uncommon. Besides, drugs currently used to treat the COVID-19 are known to prolong the QT interval and can have a proarrhythmic propensity. This review focus on COVID-19 cardiac and arrhythmic manifestations and, in parallel, makes an appraisal of other virus epidemics as SARS-CoV, Middle East respiratory syndrome coronavirus, and H1N1 influenza.

Cardiac and arrhythmic complications in patients with COVID-19 / A.N. Kochi, A.P. Tagliari, G.B. Forleo, G.M. Fassini, C. Tondo. - In: JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY. - ISSN 1045-3873. - 31:5(2020 May), pp. 1003-1008. [10.1111/jce.14479]

Cardiac and arrhythmic complications in patients with COVID-19

C. Tondo
2020

Abstract

In December 2019, the world started to face a new pandemic situation, the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). Although coronavirus disease (COVID-19) clinical manifestations are mainly respiratory, major cardiac complications are being reported. Cardiac manifestations etiology seems to be multifactorial, comprising direct viral myocardial damage, hypoxia, hypotension, enhanced inflammatory status, ACE2-receptors downregulation, drug toxicity, endogenous catecholamine adrenergic status, among others. Studies evaluating patients with COVID-19 presenting cardiac injury markers show that it is associated with poorer outcomes, and arrhythmic events are not uncommon. Besides, drugs currently used to treat the COVID-19 are known to prolong the QT interval and can have a proarrhythmic propensity. This review focus on COVID-19 cardiac and arrhythmic manifestations and, in parallel, makes an appraisal of other virus epidemics as SARS-CoV, Middle East respiratory syndrome coronavirus, and H1N1 influenza.
arrhythmia; COVID-19; myocardial damage; myocarditis; SARS-CoV-2; Arrhythmias, Cardiac; Betacoronavirus; Cardiomyopathies; Coronavirus Infections; Humans; Male; Myocarditis; Pandemics; Pneumonia, Viral; Coronavirus
Settore MED/11 - Malattie dell'Apparato Cardiovascolare
mag-2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
jce.14479.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 700.78 kB
Formato Adobe PDF
700.78 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/755310
Citazioni
  • ???jsp.display-item.citation.pmc??? 311
  • Scopus 423
  • ???jsp.display-item.citation.isi??? 367
social impact